Biothera

Company

Also known as: Bio-Thera

Related News

STADA and Bio-Thera Receive EU Approval for Gotenfia Biosimilar to Simponi

Feb 13, 2026

The European Commission has approved Gotenfia (golimumab), a biosimilar to Simponi developed by Bio-Thera and marketed by STADA, for chronic inflammatory autoimmune diseases across the EU and EEA.

STADA and Bio-Thera Receive European Marketing Authorization for Gotenfia Biosimilar

Feb 13, 2026

The European Commission has granted marketing authorization for Gotenfia, a golimumab biosimilar to Simponi, developed by Bio-Thera and to be commercialized by STADA across the EU, EEA, UK, Switzerland and selected other countries.